News

Grants

Dr. Cui received multiple grants this year:
§R01: Targeting PGC-1a for the treatment of sickle cell disease (2022-25)
§GBT Therapeutics: In vivo evaluation of GBT compounds in a mouse model (2022-23)
§Doris Duke Advancing Cures Award (Renewal): Modulation of LSD1 and PGC-1a using small molecule inhibitors to induce fetal hemoglobin (2023-25)
Cheers!

By Shuaiying CuiSeptember 6th, 2022

Welcome Kelly Liu to the Cui Lab!

Kelly Liu joined to the lab as a Master student. She will lead a project focusing on the role of HMI Lnc-RNA in globin regulation and erythroid differentiation.

Grant

By Shuaiying CuiFebruary 24th, 2022

Dr. Cui received a grant from Doris Duke Charitable Foundation for the collaboration project "Interactions between fetal hemoglobin regulation network" with the Mount Sinai School of Medicine.

Congrats! Raymon received the fall 2021 UROP Student Research Awards.

By Shuaiying CuiFebruary 24th, 2022

Raymon Chen received the fall 2021 UROP Student Research Awards. He will be leading a project focus on a novel human lncRNA with an important role in the regulation of fetal hemoglobin (HbF) with the goal of acquiring a new therapeutic target for HbF induction in patients with SCD and β-thalassemia. Targeting lncRNAs therapeutically has the advantages of increased specificity, different RNA-directed therapeutic approaches, and the possibility of small molecule inhibitors. The proposed studies would allow him to gain skills and knowledge of various cutting-edge techniques, such as lentivirus- mediated RNA interference and gene delivery to human hematopoietic stem or progenitor cells.

https://www.bumc.bu.edu/hematology/files/2021/10/Section-Newsletter-September-2021.pdf

Grant

By Shuaiying CuiMarch 26th, 2021

Dr. Cui received a supplemental grant from Doris Duke Charitable Foundation for sickle cell disease research.

Nicole and Nika

By Shuaiying CuiMarch 26th, 2021

Congratulations! Nicole Nguyen and Nika Kozlov both received the Summer 2021 UROP Awards.
Nicole's project focused on determining optimal conditions of DMNT1 Inhibitor, decitabine, to induce maximal fetal hemoglobin expression in human erythroid progenitor cells.
Nika's project focused on evaluating the in vivo effects of PGC-1a agonists, ZLN005 and SR-18292, in sickle cell disease mice.